IRIS
ADAMO, Vincenzo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.010
EU - Europa 9.828
AS - Asia 5.145
SA - Sud America 1.991
AF - Africa 148
Continente sconosciuto - Info sul continente non disponibili 15
OC - Oceania 9
Totale 27.146
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.833
RU - Federazione Russa 3.190
SG - Singapore 2.295
BR - Brasile 1.779
IE - Irlanda 1.628
SE - Svezia 1.615
CN - Cina 1.468
IT - Italia 736
HK - Hong Kong 649
DE - Germania 530
PL - Polonia 511
UA - Ucraina 498
FI - Finlandia 294
GB - Regno Unito 284
FR - Francia 246
VN - Vietnam 217
IN - India 121
AR - Argentina 86
CA - Canada 76
BE - Belgio 73
AT - Austria 60
MX - Messico 58
ZA - Sudafrica 55
BD - Bangladesh 44
IQ - Iraq 43
TR - Turchia 42
EC - Ecuador 37
ID - Indonesia 34
JP - Giappone 34
ES - Italia 31
UZ - Uzbekistan 30
MA - Marocco 26
NL - Olanda 26
VE - Venezuela 23
CO - Colombia 22
PK - Pakistan 22
KE - Kenya 17
CZ - Repubblica Ceca 16
TN - Tunisia 15
AE - Emirati Arabi Uniti 14
PY - Paraguay 13
DO - Repubblica Dominicana 12
LT - Lituania 12
AL - Albania 11
AZ - Azerbaigian 11
IL - Israele 11
JO - Giordania 11
NP - Nepal 11
JM - Giamaica 10
KZ - Kazakistan 10
DZ - Algeria 9
IR - Iran 9
KG - Kirghizistan 9
BO - Bolivia 8
EG - Egitto 8
EU - Europa 8
PE - Perù 8
UY - Uruguay 8
BG - Bulgaria 7
CH - Svizzera 7
CL - Cile 7
LV - Lettonia 7
OM - Oman 7
CI - Costa d'Avorio 6
HR - Croazia 6
RS - Serbia 6
SA - Arabia Saudita 6
SK - Slovacchia (Repubblica Slovacca) 6
AU - Australia 5
CR - Costa Rica 5
GE - Georgia 5
HN - Honduras 5
PS - Palestinian Territory 5
XK - ???statistics.table.value.countryCode.XK??? 5
HU - Ungheria 4
LB - Libano 4
MY - Malesia 4
NI - Nicaragua 4
NZ - Nuova Zelanda 4
PH - Filippine 4
TH - Thailandia 4
AM - Armenia 3
AO - Angola 3
BN - Brunei Darussalam 3
DK - Danimarca 3
GA - Gabon 3
GR - Grecia 3
LU - Lussemburgo 3
MN - Mongolia 3
NO - Norvegia 3
PA - Panama 3
RO - Romania 3
A2 - ???statistics.table.value.countryCode.A2??? 2
BA - Bosnia-Erzegovina 2
EE - Estonia 2
GT - Guatemala 2
LA - Repubblica Popolare Democratica del Laos 2
LK - Sri Lanka 2
MK - Macedonia 2
ML - Mali 2
Totale 27.129
Salva come PNG Salva come JPEG
Città #
Moscow 1.627
Dublin 1.622
Chandler 1.375
Singapore 1.178
Ashburn 1.079
Dallas 1.068
Jacksonville 1.010
Nyköping 847
Hong Kong 649
Beijing 626
Warsaw 496
New York 339
Ann Arbor 277
Princeton 272
Medford 259
Dearborn 250
Los Angeles 247
Cambridge 240
Des Moines 208
The Dalles 200
Messina 170
Boardman 167
São Paulo 142
Buffalo 134
Munich 93
Woodbridge 84
Jinan 83
Tianjin 82
Brussels 71
Lancaster 70
Wilmington 61
Pune 58
Ho Chi Minh City 57
Rio de Janeiro 56
Redondo Beach 55
Shenyang 55
Belo Horizonte 53
San Mateo 53
Hanoi 49
Frankfurt am Main 48
Vienna 47
Dong Ket 46
Brooklyn 43
Nanjing 42
Johannesburg 36
Hebei 34
Houston 34
Zhengzhou 33
Brasília 32
Council Bluffs 32
Turku 30
London 29
Montreal 29
Tashkent 28
Tokyo 28
San Francisco 27
Seattle 27
Stockholm 27
Porto Alegre 26
Haikou 25
Helsinki 25
Jakarta 25
Nuremberg 24
Santa Clara 24
Hangzhou 23
Boston 22
Campinas 21
Nanchang 21
Atlanta 20
Changsha 20
Goiânia 20
Guangzhou 20
Denver 19
Leawood 19
Mexico City 19
Ningbo 19
Taizhou 19
Curitiba 18
Jiaxing 18
Quito 18
Chennai 17
Düsseldorf 17
Guarulhos 17
Milan 17
Hyderabad 16
Nairobi 16
Orem 16
San Jose 16
Taiyuan 16
Toronto 16
Washington 16
Baghdad 15
Chicago 15
Fuzhou 14
Grammichele 14
Manchester 14
Rome 14
Sorocaba 14
São Bernardo do Campo 14
Ankara 13
Totale 16.886
Salva come PNG Salva come JPEG
Nome #
PARAGANGLIOMA MALIGNO DEL CORPO CAROTIDEO.Rilievi Clinici, Morfologici, Istochimici E Ultrastrutturali Su Un Caso. 408
A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): old successes and future perspectives 191
Breast safety and efficacy of genistein aglycone for postmenopausal bone loss: a follow-up study 185
Validation of the OAKS prognostic model for acute kidney injury after gastrointestinal surgery 184
Prognostic value of methlylenetetrahydrofolate reductase (MTHFR), thymidylate synthase (TS) promoter, and p53 codon 72 variants and survival in advanced non-small cell lung cancer (NSCLC). 182
Su di un caso di pseudomyxoma peritonei con diffusione spontanea alla pleura. 179
zd1839"iressa" in heavily pretreated patients with advaned/metastatic non-small cell lung cancer(NSCLC):assessment of tolerability and the clinical benefit 176
Androgen Receptor (AR), E-Cadherin, and Ki-67 as emerging targets and novel prognostic markers in triple-negative breast cancer (TNBC) patients 172
Activity of pegylated liposomal doxorubicin in combination with gemcitabine in triple negative breast cancer with skin involvement: Two case reports. 171
Baseline neutrophilia, derived neutrophil-to-lymphocyte ratio (dNLR), platelet-to-lymphocyte ratio (PLR), and outcome in non small cell lung cancer (NSCLC) treated with Nivolumab or Docetaxel 168
An immunohistochemical investigation of pre-metastatic niche (PMN) in node-negative invasive breast carcinomas 160
The prognostic significance of combined androgen receptor, E-Cadherin, Ki67 and CK5/6 expression in patients with triple negative breast cancer 160
Androgen receptor (AR), E-cadherin, and Ki-67 as prognostic markers in triple-negative breast cancer (TNBC). 157
Activity and safety of gefitinib and erlotinib in metastatic non-small cell lung cancer (NSCLC): A comparative analysis. 156
Epirubucin (EPI) and Paclitaxel (TAX) in advanced breast cancer.a phase II studyi 154
[Serum levels of copper and zinc in patients with lung cancer] 154
Impact of integrated treatments on patient management in solid tumors: from diagnosis to palliative care. 150
Interleukin-22 serum concentration in colon-rectal cancer patients and clinical correlations: our experience. 150
A study of endometrial adenocarcinoma treated with tamoxifen by scanning and transmission electron microscopy. 148
Correction to: Changes in surgicaL behaviOrs dUring the CoviD-19 pandemic. The SICE CLOUD19 Study 147
Intralesional sonographically guided injections of lymphokine- activated killer cells and recombinant interleukin-2 for the treatment of liver tumors: A pilot study 146
ACTIVITY AND TOXICITY OF GEMCITABINE AND GEMCITABINE + VINORELBINE IN ADVANCED NSCLC EDERLY PATIENTS .PHASE II DATA FROM THE MULTICENTER ITALIAN LUNG CANCER IN THE ELDERLY STUDY(MILES) RANDOMIZED TRIAL 144
Folate pathway implications in advanced Non Small Cell Lung Cancer (NSCLC): impact of thymidylate synthase (TS) promoter and methlylenetetrahydrofolate reductase (MTHFR) C677T and A1298C variants expression on patients’ outcome and correlation with p53 codon 72 mutations. 144
Phase II study of gemcitabine and cisplatin in patients with advanced or metastatic bladder cancer: long-term follow-up of a 3-week regimen 142
A PHASE II STUDY (21 DAY REGIMEN) OF GEMCITABINE AND CISPLATIN IN TRANSITIONAL CELL CARCINOMA OF BLADDER 142
Changes in surgicaL behaviOrs dUring the CoviD-19 pandemic. The SICE CLOUD19 Study 141
Gemcitabine (GEM) and cisplatin (CIS) in advanced/metastatic transitional cell carcinoma (TCC) of bladder:phase II study 140
Evaluation of quality of life of patients submitted to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinosis of gastrointestinal and ovarian origin and identification of factors influencing outcome. 140
Bleomycin, epirubicin, carboplatin (BECA) in the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck 139
Interleukin-22 serum concentration in colon-rectal cancer patients and clinical correlations: our experience. 139
HER-2 overexpression in advanced node-positive gastric carcinomas: is there any relationship with other clinico-pathological histoprognostic parameters? 139
The treatment of peritoneal carcinomatosis in elderly patients. 138
A new method for titration of oral transmucosal fentanyl citrate (OTFC) starting dose in cancer patients. 137
Preliminary study of pre-metastatic niche (PMN) in nonmetastatic nodes for the assessment of metastasis risk in breast cancer (BC). 137
SPONTANEOUS TRANSFORMATION AND IMMORTALIZATION OF PERITONEAL- MACROPHAGES OF HUMAN-ORIGIN 137
Heterogeneous responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with uncommon EGFR mutations: New insights and future perspectives in this complex clinical scenario 137
Clinical significance of circulating interleukin-23 as a prognostic factor in breast cancer patients. 136
A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: A real-world experience 136
Bone health assessment by quantitative ultrasound and dual-energy x-ray absorptiometry in postmenopausal women with breast cancer receiving aromatase inhibitors 135
Activity and tolerability of cisplatin (CDDP) and fotemustine (FTM) in non-small cell lung cancer (NSCLC) patients (PTS) with brain metastases (BM): A multicentric phase II study of the Gruppo Oncologico dell'Italia Meridionale (GOIM). 134
Intralesional sonographically guided injections of lymphokine-activated killer cells and recombinant interleukin-2 for the treatment of liver tumors: a pilot study. 134
Nab-paclitaxel and trastuzumab combination: A promising approach for neoadjuvant treatment in HER2-positive breast cancer 134
Can we better manage advanced NSCLC in the elderly with the new therapeutic agents? Preliminary analysis of a real life multicenter study. 134
A randomised factorial trial of sequential doxorubicin and CMF vs CMF and chemotherapy alone vs chemotherapy followed by goserelin plus tamoxifen as adjuvant treatment of node-positive breast cancer. 133
Antiblastic treatment of advanced cervical carcinoma and its recurrences: assessment of four different polychemotherapies used for a decade. 133
Breast. La terapia primaria: stato dell'arte 132
AIOM Conference 2004. Docetaxel: a recent conquest in the adjuvant therapy of breast cancer 131
Brain metastases in patients with non-small cell lung cancer: focus on the role of chemotherapy. 131
Circulating miR-22, miR-24 and miR-34a as novel predictive biomarkers to pemetrexed-based chemotherapy in advanced non small cell lung cancer. 131
Immunoexpression of lactoferrin in triple-negative breast cancer patients: A proposal to select a less aggressive subgroup 131
Hereditary breast/ovarian cancer families: The impact of mutation prediction models on BRCA1/2 mutation screening costs. 130
ZD 1839 IRESSA IN HEAVILY PRETREATED PATIENTS WITH ADVANCED/METASTATIC NON SMALL CELL LUNG CANCER:ASSESSMENT OF TOLERABILITY AND CLINICAL BENEFIT 130
Is the adenocarcinoma subtype a predictor of response to Pemetrexed in patients with non small cell lung cancer? Our preliminary data 130
gemcitabine and pegylated liposomial doxorubicin in recurrent epithelial ovarian cancer (REOC).Preliminary report a phase II study 130
Efficacy of T-DM1 for leptomeningeal and brain metastases in a HER2 positive metastatic breast cancer patient: New directions for systemic therapy - a case report and literature review 130
VP16, epirubicin and procarbazine in the treatment of advanced non-small-cell lung cancer. 129
Etoposide, l-leucovorin and fluorouracil (ELF) regimen in metastatic gastric cancer: a phase II study. J Chemother. 1999 Feb;11(1):74-7. PMID: 10078785 [PubMed - indexed for MEDLINE] 129
Detection Of Lynphocytic β - Endorphin In Cancer Patients During Hospedalization And After In Vitro Culture With IL 2. 129
A double-blind randomized study comparing intramuscular (i.m.) granisetron with i.m. granisetron plus dexamethasone in the prevention of delayed emesis induced by cisplatin 128
Gemcitabine (GEM) and cisplatin (Cis) in advanced/metastatic transitional cell carcinoma (TCC) of bladder: Phase II study 128
Is the adenocarcinoma subtype a predictor of response to Pemetrexed in patients with non small cell lung cancer? Our preliminary data. 128
Epidermal growth factor receptor (EGFR) G719C mutation as new determinant of long term survival and response in patients with non small cell lung cancer treated with erlotinib: 128
The palliative role of Gefitinib (Iressa) in the treatment of heavily pretreated patients with advanced, refractory non small cell lung cancer. Results of a 3-year experience. 127
Gefitinib versus Erlotinib treatment in Non Small Cell Lung Cancer (NSCLC): comparison of two clinical experiences. 127
Emerging role of Radium-223 in the growing therapeutic armamentarium of metastatic castration-resistant prostate cancer 127
FCM detection of lymphocytic beta-endorphin in cancer patients during hospitalization and after in vitro culture with IL2 126
Il ruolo dell'ormonoterapia nel carcinoma della mammella in eta' geriatrica 126
An observational time and motion study of denosumab subcutaneous injection and zoledronic acid intravenous infusion in patients with metastatic bone disease: results from three European countries 126
Second-line therapy in advanced non-small cell lung cancer: Cytotoxic agents or tyrosine kinase inhibitors? Our experience. 125
Combination of Gemcitabine (GEM and Liposomal Pegylate Doxorubicin (PLD) in recurrent/ metastatic breast carcinoma: a phase II study. 124
Central nervous system involvement in ALK-rearranged NSCLC: promising strategies to overcome crizotinib resistance 124
Maintenance Therapy with Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients with RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial 124
A phase I/II trial of gefitinib and radiotherapy in patients with locally advanced inoperable squamous cell carcinoma of the head and neck. 123
Etoposide, l-leucovorin and fluorouracil (ELF) regimen in metastatic gastric cancer: A phase II study 123
Trattamento palliativo dei tumori del retto-sigma mediante elettrocoagulazione endoscopica.” 123
Influence of EGFR mutational status on metastatic behavior in non squamous non small cell lung cancer 123
Author Correction to: Prevalence of Use and Cost of Biological Drugs for Cancer Treatment: A 5-Year Picture from Southern Italy 123
Safety of Capecitabine plus Bevacizumab in heavily treated patients with metastatic colorectal cancer (MCRC) 122
CyberKnife Radiosurgery Alone or Combined with "Dose Dense" Temozolomide Administration for Recurrent Gliomas. 122
Biological parameters in breast cancer. 122
Correlation between serum magnesium levels and skin toxicity during cetuximab treatment in squamous cell carcinoma of head and neck cancer (SCCHN): the role of weekly intravenous magnesium supplementation. 121
Unusual relapse of hepatocellular carcinoma 121
Extended RAS mutation testing on wild-type KRAS exon 2 metastatic colorectal cancer. 119
Third generation EGFR TKIs in EGFR-mutated NSCLC: Where are we now and where are we going 119
Current knowledge and future directions on bisphosphonate-related osteonecrosis of the jaw in cancer patients 118
TCC superficiale della vescica: identificazione nel sedimento urinario di mediatori di proliferazione cellulare quali possibili indici di recidiva e progressione neoplastica. 118
Long time response with chemotherapy in ROS1 NSCLC patient with unusual metastatic site 118
Peritoneal carcinomatosis of colorectal origin. 117
I Tumori del coloretto. La chemioterapia della fase avanzata. 116
Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial. 116
NSCLC and HER2: between lights and shadows 115
Correction: Androgen Receptor (AR), E-cadherin, and Ki-67 as emerging targets and novel prognostic markers in Triple-Negative Breast Cancer (TNBC) patients 115
The Mam-1 GOCSI Trial: a Randomised Trial with Factorial Design of Chemo-Endocrine Adjuvant Treatment in Node-Positive (N+) Early Breast Cancer (EBC). 112
Paclitaxel and cisplatin in patients with recurrent and metastatic head and neck squamous cell carcinoma. 112
Metastasis risk assessment in breast cancer (BC): a preliminary study of pre-metastatic niche (PMN) in nonmetastatic nodes 112
Induction chemotherapy with paclitaxel and cisplatin to concurrent radiotherapy and weekly paclitaxel in the treatment of loco-regionally advanced, stage IV (M0), head and neck squamous cell carcinoma. Mature results of a prospective study. 112
Impact of integrated treatments on patient management in solid tumors: From diagnosis to palliative care. 111
The changing scenario of 1st line therapy in non-oncogene addicted NSCLCs in the era of immunotherapy 111
Gemcitabine and liposomal doxorubicin in the salvage treatment of ovarian cancer: Updated results and long-term survival. 110
Comment on "Clinical genetic testing for familial melanoma in Italy: a cooperative study". 110
Totale 13.748
Salva come PNG Salva come JPEG
Categoria #
all - tutte 94.321
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 94.321
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.137 0 0 0 0 0 223 115 159 77 238 193 132
2021/20221.776 19 244 30 45 58 16 106 65 15 320 265 593
2022/20235.031 390 493 216 420 382 514 80 329 1.989 19 141 58
2023/20241.304 103 186 70 108 71 498 66 56 5 46 11 84
2024/20255.083 66 47 92 316 259 168 106 1.120 1.345 293 418 853
2025/20268.284 753 925 1.077 859 1.254 3.416 0 0 0 0 0 0
Totale 27.432